Synthetic Biotic
December 20, 2016 | Terry Sharrer
Sometime in 2017, a Cambridge, MA company, Synlogic, plans to carry out the first clinical trial using synthetic biology—which in this case will be a genetically engineered E. coli designed to absorb ammonia in the gut and convert it into a harmless amino acid. 100 million bacteria will be delivered in a swallowable capsule. Other labs are working with the same idea to use engineered salmonella to deliver anti-cancer drugs or treat phenylalanine. MORE
Image Credit: Synlogic